U.S. markets open in 5 hours 7 minutes
  • S&P Futures

    3,839.50
    +5.50 (+0.14%)
     
  • Dow Futures

    30,975.00
    +39.00 (+0.13%)
     
  • Nasdaq Futures

    11,831.50
    +23.00 (+0.19%)
     
  • Russell 2000 Futures

    1,743.30
    +1.60 (+0.09%)
     
  • Crude Oil

    100.99
    +1.49 (+1.50%)
     
  • Gold

    1,769.80
    +5.90 (+0.33%)
     
  • Silver

    19.32
    +0.20 (+1.04%)
     
  • EUR/USD

    1.0264
    -0.0006 (-0.06%)
     
  • 10-Yr Bond

    2.8090
    0.0000 (0.00%)
     
  • Vix

    27.72
    +0.19 (+0.69%)
     
  • GBP/USD

    1.1979
    +0.0027 (+0.23%)
     
  • USD/JPY

    135.2580
    -0.5840 (-0.43%)
     
  • BTC-USD

    20,197.15
    +91.36 (+0.45%)
     
  • CMC Crypto 200

    437.52
    -2.50 (-0.57%)
     
  • FTSE 100

    7,172.98
    +147.51 (+2.10%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Adicet Bio to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif. & BOSTON, June 21, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in June.

Details of the events are as follows:

Truist Securities Cell Therapy Symposium, Symposia-cel, June 28, 2022

  • Chen Schor, President & CEO, will participate in a panel discussion titled, "The Next Cells & Mechanisms to Watch in Oncology" on Tuesday, June 28, 2022, at 11:30 A.M. ET.

Stifel 2022 Virtual Cell Therapy Summit, June 29-30, 2022

  • Chen Schor, President & CEO, will participate in a panel discussion titled, "Outlining the Potential of New Cell Types and Novel Approaches" on Wednesday, June 29, 2022, at 1:00 P.M. ET.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005986/en/

Contacts

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com